Tag: their-world
-
Exclusive: Pfizer weighs sale or spin-off of consumer health unit – sources
By Lauren Hirsch, Olivia Oran and Carl O'Donnell (Reuters) – U.S. drugmaker Pfizer Inc is evaluating a potential sale or spin-off of its consumer health division that could value the unit at as much as $14 billion, people familiar with the matter said on Wednesday. A Pfizer exit from the consumer health business, which includes…
-
Mylan working to finalize EpiPen Medicaid settlement: CFO
Generic drugmaker Mylan NV said on Wednesday it was working to finalize a settlement with the U.S. government over Medicaid rebates for its EpiPen emergency allergy treatment, adding that money set aside for the settlement led to a third quarter loss. The company had previously said it agreed to terms of a settlement set at…
-
ICU Medical to buy Pfizer’s infusion therapy business
(Reuters) – Medical device maker ICU Medical Inc said it would buy Pfizer Inc's global infusion therapy business, Hospira Infusion Systems, for $1 billion in cash and stock. Pfizer will receive $600 million in cash and nearly $400 million in newly issued shares of ICU Medical common stock, giving the drugmaker a stake of about…
-
Polish parliament rejects near-total abortion ban after protests
By Pawel Sobczak and Marcin Goettig WARSAW (Reuters) – Following protests by tens of thousands of women, Polish lawmakers on Thursday rejected plans for a near-total ban on abortion, in a hastily arranged vote that marks the first major domestic setback for the conservative government. The ruling Law and Justice party (PIS) unexpectedly withdrew its…
-
FDA panel recommends dropping serious warning on Pfizer’s Chantix
Pfizer's Chantix was approved about a decade ago, but thousands of reports of mental health problems in users led to the FDA imposing the “black box” warning – the most severe available – in 2009. On Wednesday, four of the 19 panelists voted to update the language in the box warning – of neuropsychiatric risks…
-
Pfizer boosts cancer drug roster with $14 billion Medivation deal
Medivation shares jumped nearly 20 percent to close at $80.42, just shy of the offer price of $81.50 per share. Shares of Pfizer, the largest U.S. drugmaker, were down 0.4 percent at $34.84. The offer is a 55-percent premium to Sanofi SA's initial bid to buy Medivation for $52.50 per share in April, which pushed…